These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33565088)

  • 1. Antimicrobial Dose Selection under the Animal Rule.
    Wu K; Choi SY; Bergman K; Seo S
    Clin Pharmacol Ther; 2021 Apr; 109(4):971-976. PubMed ID: 33565088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule.
    Temrikar ZH; Golden JE; Jonsson CB; Meibohm B
    Clin Pharmacokinet; 2023 Jul; 62(7):943-953. PubMed ID: 37326917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule.
    Bergman KL; Krudys K; Seo SK; Florian J
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):153-160. PubMed ID: 28299529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing efficacy of human products using animals: the US food and drug administration's "animal rule".
    Snoy PJ
    Vet Pathol; 2010 Sep; 47(5):774-8. PubMed ID: 20551476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose.
    Bergman KL
    Clin Pharmacol Ther; 2009 Sep; 86(3):328-31. PubMed ID: 19571806
    [No Abstract]   [Full Text] [Related]  

  • 6. Working with the U.S. Food and Drug Administration to obtain approval of products under the Animal Rule.
    Park GD; Mitchel JT
    Ann N Y Acad Sci; 2016 Jun; 1374(1):10-6. PubMed ID: 27336401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pivotal Role of Translation in Anti-Infective Development.
    Friberg LE
    Clin Pharmacol Ther; 2021 Apr; 109(4):856-866. PubMed ID: 33523464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Product Development Under FDA's Animal Rule: Understanding FDA's Expectations and Potential Implications for Traditional Development Programs.
    Allio T
    Ther Innov Regul Sci; 2016 Sep; 50(5):660-670. PubMed ID: 30231765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delegations of authority and organization; Center for Devices and Radiological Health--FDA. Final rule.
    Fed Regist; 1991 Oct; 56(197):51169-70. PubMed ID: 10115059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule.
    Bai JPF; Hsu CW
    J Pharm Sci; 2019 Feb; 108(2):798-806. PubMed ID: 30244014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory utility of pharmacometrics in the development and evaluation of antimicrobial agents and its recent progress in China.
    Zhao M; Chen Y; Yang D; Lyu C; Bian X; Li X; Qiu W; Huang Z; Hu Z; Zhang J
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1466-1478. PubMed ID: 34651458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA's new drug evaluation process: a general overview.
    Walters PG
    J Public Health Dent; 1992; 52(6):333-7. PubMed ID: 1432918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-infective agents, biologics, and vaccines approved by the U.S. Food and Drug Administration's Center for Drug Evaluation and Research in 1993.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):908. PubMed ID: 8031072
    [No Abstract]   [Full Text] [Related]  

  • 16. The animal rule: The role of clinical pharmacology in determining an effective dose in humans.
    Bergman KL
    Clin Pharmacol Ther; 2015 Oct; 98(4):365-8. PubMed ID: 26082064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory Considerations for the Approval of Drugs Against Histomoniasis (Blackhead Disease) in Turkeys, Chickens, and Game Birds in the United States.
    Regmi PR; Shaw AL; Hungerford LL; Messenheimer JR; Zhou T; Pillai P; Omer A; Gilbert JM
    Avian Dis; 2016 Dec; 60(4):725-730. PubMed ID: 27902913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the US Food and Drug Administration's reform legislation.
    Rheinstein PH
    Clin Ther; 1998; 20 Suppl C():C4-11. PubMed ID: 9915084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco.
    Berman ML; Hatsukami DK
    Tob Control; 2018 May; 27(3):352-354. PubMed ID: 28634163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.